Tardive Dyskinesia Involuntary Movement Study
Start Date 2014-10-22
End Date 2016-07-01
Eligibility Requirements
Eligibility
Gender
Gender
Male
Female
Age Range
Age Range
18 - 25 years
26 - 30 years
31 - 45 years
56 and more years
Vetaran Status
Vetaran Status
Service Range
Service Range
Deployment Status
Deployment Status
Military Affiliation
Military Affiliation
Short Description
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
Location Info
Conducted in
Oakland , California
Privacy of the Participants
Does this study require the individual's medical records? - Yes
Does the sponsor require the name of study participants to be provided? - Yes
Is this study required to provide individual results to the sponsor? - Yes
Is this study anonymous in the sense that patient identity is completely anonymized? - Yes
Contact Details
Cheri Savercool 877-602-5777 [email protected]
Research Topics
Mental Health
More Info
Has this study and the posting of this study on AllyResearch.org been IRB approved - Yes
Are healthy subjects accepted? - No
Does this study utilize any drug treatments? - Yes
Are there financial incentives to participate? - Yes
Financial Incentive for this study :
Official title: A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia (KINECT 3)
University IRB
N/A
Study ID #
NCT02274558
Lead Researcher
Ira, Glick
Sponsored By
Neurocrine